156 related articles for article (PubMed ID: 27638528)
1. [New prognostic and predictive markers for breast cancer].
Wachter DL
Pathologe; 2016 Nov; 37(Suppl 2):217-222. PubMed ID: 27638528
[TBL] [Abstract][Full Text] [Related]
2. [Neuroendocrine differentiation in breast cancer].
Kreipe HH
Pathologe; 2019 Dec; 40(Suppl 3):325-330. PubMed ID: 31781853
[TBL] [Abstract][Full Text] [Related]
3. Effect of Ki-67 on Immunohistochemical Classification of Luminal A to Luminal B Subtypes of Breast Carcinoma.
Cirqueira MB; Moreira MA; Soares LR; Cysneiros MA; Vilela MH; Freitas-Junior R
Breast J; 2015; 21(5):465-72. PubMed ID: 26138552
[TBL] [Abstract][Full Text] [Related]
4. [What is new in the pathology of pancreatic neuroendocrine tumors?].
Komminoth P; Perren A
Pathologe; 2015 May; 36(3):220-8. PubMed ID: 25941099
[TBL] [Abstract][Full Text] [Related]
5. [Are the new breast cancer subtypes (luminal A, B etc.) of practical impact? No].
Gampenrieder SP
Dtsch Med Wochenschr; 2013 Oct; 138(41):2097. PubMed ID: 24085365
[No Abstract] [Full Text] [Related]
6. Expression of neuroendocrine markers in different molecular subtypes of breast carcinoma.
Wachter DL; Hartmann A; Beckmann MW; Fasching PA; Hein A; Bayer CM; Agaimy A
Biomed Res Int; 2014; 2014():408459. PubMed ID: 24701575
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of the progesterone receptor status in Ki67-high and -low Luminal B-like HER2-negative breast cancers.
Sato K; Miyashita M; Ishida T; Suzuki A; Tada H; Watanabe G; Sato-Tadano A; Watanabe M; Ohuchi N
Breast Cancer; 2016 Mar; 23(2):310-7. PubMed ID: 25380989
[TBL] [Abstract][Full Text] [Related]
8. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
Nishimukai A; Yagi T; Yanai A; Miyagawa Y; Enomoto Y; Murase K; Imamura M; Takatsuka Y; Sakita I; Hatada T; Miyoshi Y
Clin Breast Cancer; 2015 Jun; 15(3):204-11. PubMed ID: 25600243
[TBL] [Abstract][Full Text] [Related]
9. [Are the new breast cancer subtypes (luminal A, B etc.) of practical impact? Yes].
Stöger H
Dtsch Med Wochenschr; 2013 Oct; 138(41):2096. PubMed ID: 24085364
[No Abstract] [Full Text] [Related]
10. Specific cell differentiation in breast cancer: a basis for histological classification.
Rakha E; Toss M; Quinn C
J Clin Pathol; 2022 Feb; 75(2):76-84. PubMed ID: 34321225
[TBL] [Abstract][Full Text] [Related]
11. Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013.
Ehinger A; Malmström P; Bendahl PO; Elston CW; Falck AK; Forsare C; Grabau D; Rydén L; Stål O; Fernö M;
Acta Oncol; 2017 Jan; 56(1):68-74. PubMed ID: 27762648
[TBL] [Abstract][Full Text] [Related]
12. p63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas.
Matos I; Dufloth R; Alvarenga M; Zeferino LC; Schmitt F
Virchows Arch; 2005 Oct; 447(4):688-94. PubMed ID: 16012853
[TBL] [Abstract][Full Text] [Related]
13. [Neuroendocrine tumors of the kidneys].
Moch H
Pathologe; 2015 May; 36(3):278-82. PubMed ID: 25898936
[TBL] [Abstract][Full Text] [Related]
14. Subclassification of the molecular types of breast cancer based on the expression of immunohistochemical markers and evolution.
Reigosa A; Hardisson D; Sanzi F; Caleiras E; Saldivia F; Fernández A
Invest Clin; 2016 Jun; 57(2):187-216. PubMed ID: 28429898
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological classification and traditional prognostic indicators of breast cancer.
Li J; Chen Z; Su K; Zeng J
Int J Clin Exp Pathol; 2015; 8(7):8500-5. PubMed ID: 26339424
[TBL] [Abstract][Full Text] [Related]
16. [Histological grading of breast cancer].
Christgen M; Länger F; Kreipe H
Pathologe; 2016 Jul; 37(4):328-36. PubMed ID: 27363708
[TBL] [Abstract][Full Text] [Related]
17. Molecular classification of breast cancer: what the pathologist needs to know.
Rakha EA; Green AR
Pathology; 2017 Feb; 49(2):111-119. PubMed ID: 28040199
[TBL] [Abstract][Full Text] [Related]
18. The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence.
Ignatiadis M; Azim HA; Desmedt C; Veys I; Larsimont D; Salgado R; Lyng MB; Viale G; Leyland-Jones B; Giobbie-Hurder A; Kammler R; Dell'Orto P; Rothé F; Laïos I; Ditzel HJ; Regan MM; Piccart M; Michiels S; Sotiriou C
JAMA Oncol; 2016 Feb; 2(2):217-24. PubMed ID: 26633571
[TBL] [Abstract][Full Text] [Related]
19. Ki-67 as a controversial predictive and prognostic marker in breast cancer patients treated with neoadjuvant chemotherapy.
Ács B; Zámbó V; Vízkeleti L; Szász AM; Madaras L; Szentmártoni G; Tőkés T; Molnár BÁ; Molnár IA; Vári-Kakas S; Kulka J; Tőkés AM
Diagn Pathol; 2017 Feb; 12(1):20. PubMed ID: 28222768
[TBL] [Abstract][Full Text] [Related]
20. Expression of proliferation genes in formalin-fixed paraffin-embedded (FFPE) tissue from breast carcinomas. Feasibility and relevance for a routine histopathology laboratory.
Thomas C; Robinson C; Dessauvagie B; Wood B; Sterrett G; Harvey J; Amanuel B
J Clin Pathol; 2017 Jan; 70(1):25-32. PubMed ID: 27235535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
